[go: up one dir, main page]

NO2019008I1 - Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav - Google Patents

Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav

Info

Publication number
NO2019008I1
NO2019008I1 NO2019008C NO2019008C NO2019008I1 NO 2019008 I1 NO2019008 I1 NO 2019008I1 NO 2019008 C NO2019008 C NO 2019008C NO 2019008 C NO2019008 C NO 2019008C NO 2019008 I1 NO2019008 I1 NO 2019008I1
Authority
NO
Norway
Prior art keywords
lesinurad
allopurinol
salts
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO2019008C
Other languages
English (en)
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2019008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of NO2019008I1 publication Critical patent/NO2019008I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO2019008C 2010-06-15 2019-02-19 Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav NO2019008I1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (1)

Publication Number Publication Date
NO2019008I1 true NO2019008I1 (no) 2019-02-19

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2019008C NO2019008I1 (no) 2010-06-15 2019-02-19 Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav

Country Status (19)

Country Link
US (3) US9216179B2 (no)
EP (1) EP2582683B1 (no)
JP (1) JP5964821B2 (no)
CA (1) CA2802407C (no)
CY (1) CY1120473T1 (no)
DK (1) DK2582683T3 (no)
ES (1) ES2670700T3 (no)
HR (1) HRP20180780T1 (no)
HU (1) HUE038265T2 (no)
LT (1) LT2582683T (no)
NO (1) NO2019008I1 (no)
PL (1) PL2582683T3 (no)
PT (1) PT2582683T (no)
RS (1) RS57275B1 (no)
SI (1) SI2582683T1 (no)
SM (1) SMT201800266T1 (no)
TR (1) TR201806828T4 (no)
WO (1) WO2011159732A1 (no)
ZA (1) ZA201300055B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
EP2776028B1 (en) 2011-11-03 2018-10-17 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
US9969701B2 (en) 2013-12-20 2018-05-15 Crystal Pharmatech Co., Ltd. Salts and co-crystals of lesinurad
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
HK1256256A1 (zh) * 2015-12-08 2019-09-20 Ardea Biosciences, Inc. 包含urat1的有效抑制剂的药物组合物
US11700979B2 (en) 2018-10-26 2023-07-18 The Procter & Gamble Company Sanitary tissue product rolls
CA3060180A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060211C (en) 2018-10-26 2025-05-13 The Procter & Gamble Company TOILET PAPER ROLLS
CA3060193C (en) 2018-10-26 2023-05-09 The Procter & Gamble Company Paper towel rolls
US20220288038A1 (en) * 2019-08-21 2022-09-15 The University Of Tokyo Abcc11 inhibitor
CN110824067B (zh) * 2019-12-11 2024-12-27 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4914611B2 (ja) 2003-12-26 2012-04-11 キッセイ薬品工業株式会社 ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
ATE528001T1 (de) 2004-08-25 2011-10-15 Ardea Biosciences Inc S-triazolyl-alpha-mercaptoacetanilide als inhibitoren von hiv-umkehrtranskriptase
BRPI0806608A2 (pt) 2007-01-19 2011-09-06 Takeda Pharmaceuticals North America Inc métodos para prevenir ou reduzir o número de surtos agudos de gota utilizando inibidores xantina oxidoredutase e agentes anti-inflamatórios
CA2706858C (en) 2007-11-27 2013-12-24 Ardea Biosciences, Inc. Imidazole and triazole derivatives and methods of use
JP2012502049A (ja) * 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
CA2761335A1 (en) * 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
US8524754B2 (en) 2010-01-08 2013-09-03 Ardea Biosciences, Inc. Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio) acetate, and uses thereof
EP2560642A4 (en) 2010-03-30 2013-12-18 Ardea Biosciences Inc TREATMENT OF GICHT
EP2582683B1 (en) * 2010-06-15 2018-03-21 Ardea Biosciences, Inc. Treatment of gout and hyperuricemia
CA2803446C (en) * 2010-07-02 2019-06-04 University Health Network Use of plk4 antagonists for treating pten mutant diseases
CA2813555C (en) 2010-10-15 2014-11-25 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
HRP20170187T1 (hr) 2010-12-30 2017-03-24 Ardea Biosciences, Inc. Polimorfni oblici 2-(5-brom-4-(4-ciklopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio) octene kiseline i njihova upotreba
KR101624023B1 (ko) 2011-05-24 2016-05-24 아디아 바이오사이언스즈 인크. 고혈압 및 고요산혈증

Also Published As

Publication number Publication date
SMT201800266T1 (it) 2018-07-17
CA2802407C (en) 2018-01-23
HRP20180780T1 (hr) 2018-07-13
US20190015392A1 (en) 2019-01-17
WO2011159732A1 (en) 2011-12-22
US9216179B2 (en) 2015-12-22
HUE038265T2 (hu) 2018-10-29
PT2582683T (pt) 2018-05-25
PL2582683T3 (pl) 2018-08-31
SI2582683T1 (en) 2018-07-31
EP2582683A1 (en) 2013-04-24
US20160143889A1 (en) 2016-05-26
JP2013528650A (ja) 2013-07-11
EP2582683B1 (en) 2018-03-21
DK2582683T3 (en) 2018-06-06
ES2670700T3 (es) 2018-05-31
RS57275B1 (sr) 2018-08-31
ZA201300055B (en) 2018-05-30
TR201806828T4 (tr) 2018-06-21
CA2802407A1 (en) 2011-12-22
EP2582683A4 (en) 2014-04-30
JP5964821B2 (ja) 2016-08-03
CY1120473T1 (el) 2019-07-10
LT2582683T (lt) 2018-06-11
US20130178484A1 (en) 2013-07-11

Similar Documents

Publication Publication Date Title
NO2019008I1 (no) Allopurinol/lesinurad eller et farmasøytisk aksepterbart salt eller salter derav
NO2021033I1 (no) Selineksor eller et farmasøytisk akseptabelt salt derav
NO2023040I1 (no) Atogepant or a pharmaceutically acceptable salt thereof
NO2025034I1 (no) Remdesivir or a pharmaceutically acceptable salt or ester thereof - forlengelse
NO2025011I1 (no) Erdafitinib or a pharmaceutically acceptable salt thereof or a solvate thereof
NO2022031I1 (no) Voxelotor or a tautomer or pharmaceutically acceptable salt thereof
NO2021039I1 (no) pibrentasvir or a pharmaceutically acceptable salt thereof - forlenget SPC
NO2019019I1 (no) Doravirin eller et farmasøytisk akseptabelt salt derav
NO2021034I1 (no) pemigatinib or a pharmaceutically acceptable salt thereof
NO2022033I1 (no) Rimegepant or a pharmaceutically acceptable salt thereof
NO2020037I1 (no) alpelisib eller et farmasøytisk akseptabelt salt derav
NO2021041I1 (no) remimazolam or a pharmaceutically acceptable salt thereof
NO2022044I1 (no) daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
NO2023023I1 (no) Maralixibat, or a pharmaceutically acceptable salt thereof, in particular maralixibat chloride
NO2021040I1 (no) glecaprevir or a pharmaceutically acceptable salt or ester thereof- forlenget SPC
NO2020006I1 (no) upadacitinib or a pharmaceutically acceptable salt thereof
NO2023032I1 (en) Deucravacitinib or a pharmaceutically acceptable salt thereof
NO2019024I1 (no) Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2022010I1 (no) ripretinib, or a pharmaceutically acceptable salt thereof
FIC20240012I1 (fi) Omaveloksoloni tai sen farmaseuttisesti hyväksyttävä suola
NL301157I2 (nl) odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NO2020001I1 (no) Gilteritinib eller et salt derav
NO2019012I1 (no) Enkorafenib eller et farmasøytisk akseptabelt salt eller solvat derav
NO2020018I1 (no) Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NO2017059I1 (no) ribosiklib eller et farmasøytisk akseptabelt salt derav